Teva to buy U.S. rights to two Samsung Bioepis biosimilars

What happened

Teva Pharmaceutical and Samsung Bioepis announced an agreement for Teva to buy U.S. commercialization rights to two biosimilars, etanercept-ykro and Eticovo. Teva gains etanercept-ykro rights at closing and Eticovo rights in Q3 2027, while Samsung Bioepis keeps regulatory and manufacturing duties.

Confirmed

Global impact / market context

Teva adds two copy versions of established anti-inflammatory drugs, Remicade and Enbrel, to its U.S. portfolio without building manufacturing. Profit-sharing and milestone payments mean Teva pays less upfront but gives up some future profit, shifting more of its cash toward commercial launch costs.

Analyst inference

Biosimilars are near-copies of complex biologic drugs, usually sold at lower prices. For Pfizer, Amgen and Johnson & Johnson, whose branded drugs are referenced, added U.S. competition could pressure prices and revenue over time, though timing depends on launches and contracts.

Analyst inference

What to watch

1. Teva will make an upfront payment to Samsung Bioepis over the next three years, plus possible launch and sales-related milestone payments, with profits shared between the companies. Confirmed
2. Watch whether Teva sets a launch date and pricing strategy for etanercept-ykro, which could affect how quickly it competes with J&J's Remicade and Pfizer's Enbrel. Proposed
3. Track Eticovo's Q3 2027 U.S. rights transfer: any delay in regulatory or manufacturing handover from Samsung Bioepis could push back Teva's expected revenue. Analyst inference

Evidence

• seekingalpha.com